Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice
Michael E. Burleigh(Merck Canada Inc. (Canada)), MacRae F. Linton(Vanderbilt University), Jason D. Morrow(University of Ulster), Vladimir R. Babaev(Vanderbilt University Medical Center), Denis Riendeau(Merck Canada Inc. (Canada)), Sergio Fazio(Alzheimer's Association), Lawrence J. Marnett(Vanderbilt University), John A. Oates(Vanderbilt University), Shiva Gautam(Merck Canada Inc. (Canada)), Raymond C. Harris(Vanderbilt University Medical Center)
Cited by 278
Related Papers
Current Perspectives on Statins
|Circulation|2000|1.2k
Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids.
|Proceedings of the National Academy of Sciences|1992|736
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
|Nature|2007|732
Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis
|Nature Medicine|2001|692
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
|Journal of Clinical Investigation|1983|671